The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
In the research published in BMC Surgery, fecal elastase-1 (FE-1) test emerged as the most frequently utilized diagnostic ...
New data show that external-beam radiation therapy yielded superior local control and progression-free survival vs TACE in ...
Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow ...
The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback